Spotlight
- China: Gaining Entry
-
Pharmaceutical companies in a fierce race to bring their products to market have begun to regard economically burgeoning China as an R&D paradise.
- French Biotech: In Pursuit of Funding
-
With government funding in limited supply, biotech companies in France have developed strategies to build financial muscle and ensure their economic vision for the future.
- India's Road to Success
-
India is establishing itself as a global leader for pharmaceutical research, and increasingly, commercialization.
Development
- A World Away
-
Finding solutions for the neglected tropical diseases that affect one billion people worldwide requires not only a commitment to conduct sorely needed research, but also a rethinking of drug development’s value proposition.
- Biotechs and the Public Market
-
After a disastrous first half of 2008, the question becomes: Are IPOs still fueling the biotech industry?
- Europe: The Hard Cell
-
Stem cell research receives official funding from the European Parliament. But the opportunities this presents for EU researchers remain complex and controversial.
Management
- Outside Perspective
-
As the biopharmaceutical industry undergoes massive, transformational change, many companies are looking outside the industry to fill leadership positions.
- Simulating Science
-
Through clinical trial simulation, researchers can generate a fuller understanding of their drug and its potential effects, leading to better designed—and possibly less expensive—trials.
- Rethinking Informed Consent
-
Cultural understanding, technology and pragmatism are helping create new approaches to clinical research subject enrollment.
Commercialization
- The Meaning of Meta-Analyses
-
Meta-analyses can play a role in advancing scientific knowledge
for any given drug. But if poorly designed or hastily conducted, they can be damaging for an approved medicine.
- Same Difference
-
Across Europe, incentive programs have been designed, redesigned and implemented to encourage physicians to prescribe generic medications. Although the practice may help reduce costs, does it represent value for everyone?
- Knocking on a Difficult Door
-
Selling to managed care organizations requires an entirely different approach than traditional pharmaceutical detailing.
Web Exclusives
- Measure for Measure
-
A proposed Health Care Comparative Effectiveness Research Institute in the United States may force the biopharmaceutical industry to emphasize patient outcomes and quality of life issues when developing a new medicinal product.
- Evidence-Based Development and Smarter Sourcing
-
Jay Norman, president of Quintiles Consulting, discusses the changing landscape of drug development and suggests that better, evidence-based decisions, combined with smart sourcing strategies, will differentiate the future winners.
- An Unbalanced Burden
-
A Q&A with Dr. Kathleen Squires, director of the infectious disease department at Jefferson Medical College in Philadelphia, illuminates the gender differences in the diagnosis and treatment of HIV.
Columns
- Specialty Sales in the Global Marketplace
-
James Lennertz, head of global operations at Innovex, discusses the changing role of specialty sales reps.
- Safety through Standards
-
Paula Brown Stafford, executive vice president of global data management at Quintiles, discusses how universal data standards can help ensure better patient safety across all phases of clinical research.
- Anatomy of a Managed Partnership
-
Michel Abiteboul, vice president of global business development at NovaQuest, outlines various partnering solutions for today’s global pharmaceutical marketplace.
- >> more Columns
Special Report - June 2008
- BIOspeak
-
Jim Greenwood, president and CEO of the Biotechnology Industry Organization (BIO) and a former member of the U.S. Congress, discusses the most critical policy challenges facing the industry today.
- Which Way Forward?
-
Amidst the constant need to secure steady financing, emerging biotech companies are considering options that will not only produce a larger return, but also increase the likelihood of getting a product to market.
- The New Face of Outsourcing
-
The pressing need to control costs and reduce development timelines has led many biopharmaceutical manufacturers to increasingly outsource components of their clinical research programs.
- >> more
Web Exclusives
- Measure for Measure
-
A proposed Health Care Comparative Effectiveness Research Institute in the United States may force the biopharmaceutical industry to emphasize patient outcomes and quality of life issues when developing a new medicinal product.
- Evidence-Based Development and Smarter Sourcing
-
Jay Norman, president of Quintiles Consulting, discusses the changing landscape of drug development and suggests that better, evidence-based decisions, combined with smart sourcing strategies, will differentiate the future winners.